BackgroundCheck.run
Search For

Arash A Alizadeh, 51328 Greenfield Ave, San Mateo, CA 94403

Known as:
Arash Alizadeh
Related to:
Nosrat Alizadeh 64

Arash Alizadeh Phones & Addresses

328 Greenfield Ave, San Mateo, CA 94403    650-5711418   

Fountain Valley, CA   

4949 Battery Ln, Bethesda, MD 20814    301-9516848   

3353 Alma St, Palo Alto, CA 94306   

Stanford, CA   

Fountain Vly, CA   

Work

Company: Stanford Hospital and Clinics Address: 300 Pasteur Drive, Stanford, CA 94305

Education

School / High School: Stanford University 1999

Languages

English

Awards

Healthgrades Honor Roll

Ranks

Certificate: Hematology, 2009
Get Report
Control this profile

Mentions for Arash A Alizadeh

Career records & work history

Lawyers & Attorneys

Arash Alizadeh Photo 1

Arash Alizadeh - Lawyer

Office:
Law Office of Arash N. Alizadeh
Specialties:
Americans with Disabilities Act, Family and Medical Leave Act, Labor & Employment, Sexual Harassment, Wage and Hour Law, Whistleblower Litigation, Wrongful Termination
ISLN:
923790928
Admitted:
2015
University:
University of Maryland - College Park, B.S., 1998
Law School:
Trinity Law School, J.D., 2010

Medicine Doctors

Arash Alizadeh Photo 2

Dr. Arash A Alizadeh, Palo Alto CA - MD (Doctor of Medicine)

Specialties:
Hematology
Medical Oncology
Oncology
Address:
875 Blake Wilbur Dr, Palo Alto, CA 94304
650-4986000 (Phone) 650-7245203 (Fax)
269 Campus Dr Suite 1145, Stanford, CA 94305
650-7256423 (Phone) 650-7362282 (Fax)
Certifications:
Hematology, 2009
Internal Medicine, 2008
Medical Oncology, 2009
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
875 Blake Wilbur Dr, Palo Alto, CA 94304
269 Campus Dr Suite 1145, Stanford, CA 94305
Stanford Hospital and Clinics
300 Pasteur Drive, Stanford, CA 94305
Education:
Medical School
Stanford University
Graduated: 1999

Arash A. Alizadeh

Specialties:
Hematology/Oncology
Work:
Stanford Health Cancer Center Lymphoma Program
875 Blake Wilbur Dr, Palo Alto, CA 94304
650-7237621 (phone) 650-7259113 (fax)
Stanford Medicine Hematology Oncology
265 Campus Dr STE G2120B, Stanford, CA 94305
650-4986000 (phone) 650-7241231 (fax)
Education:
Medical School
Stanford University School of Medicine
Graduated: 2003
Conditions:
Non-Hodgkin's Lymphoma, Peripheral Nerve Disorders, Ventral Hernia
Languages:
English
Description:
Dr. Alizadeh graduated from the Stanford University School of Medicine in 2003. He works in Palo Alto, CA and 1 other location and specializes in Hematology/Oncology. Dr. Alizadeh is affiliated with Stanford Hospital.
Arash Alizadeh Photo 3

Arash Ash Alizadeh, Palo Alto CA

Specialties:
Internal Medicine
Hematology
Medical Oncology
Hematology & Oncology
Work:
Stanford University
875 Blake Wilbur Dr, Palo Alto, CA 94304Stanford University
875 Blake Wilbur Dr, Stanford, CA 94305
Education:
Stanford University (2003)
Arash Alizadeh Photo 4

Arash Ash Alizadeh, Stanford CA

Specialties:
Internist
Address:
269 Campus Dr, Stanford, CA 94305
Education:
Doctor of Medicine
Board certifications:
American Board of Internal Medicine Certification in Internal Medicine
American Board of Internal Medicine Sub-certificate in Hematology (Internal Medicine)
American Board of Internal Medicine Sub-certificate in Oncology (Internal Medicine)

Arash Alizadeh resumes & CV records

Resumes

Arash Alizadeh Photo 33

Paralegal At Jafari Law Group, Inc.

Location:
Orange County, California Area
Industry:
Legal Services
Arash Alizadeh Photo 34

Arash Alizadeh

Education:
Università Iuav Di Venezia 2011 - 2017
Arash Alizadeh Photo 35

Arash Alizadeh

Publications & IP owners

Us Patents

Synergistic Anti-Cd47 Therapy For Hematologic Cancers

US Patent:
2012028, Nov 8, 2012
Filed:
Sep 15, 2010
Appl. No.:
13/394060
Inventors:
Irving L. Weissman - Stanford CA, US
Ravindra Majeti - Stanford CA, US
Arash Ash Alizadeh - San Mateo CA, US
Mark P. Chao - Mountain View CA, US
International Classification:
A61K 39/395
A61K 51/10
C07K 16/30
A61P 35/00
A61P 35/02
US Classification:
424 149, 4241741, 5303873, 4241781
Abstract:
Methods are provided for treatment of hematologic cancers, particularly lymphomas and leukemias, including without limitation myelogenous and lymphocytic leukemias. A combination of antibodies specific for CD47; and specific for a cancer associated cell surface marker are administered to the patient, and provide for a synergistic decrease in cancer cell burden. The combination of antibodies may comprise a plurality of monospecific antibodies, or a bispecific or multispecific antibody. Markers of interest include without limitation, CD20, CD22, CD52, CD33; CD96; CD44; CD123; CD97; CD99; PTHR2; and HAVCR2.

Methods For Enhancing Anti-Tumor Antibody Therapy

US Patent:
2012032, Dec 20, 2012
Filed:
Dec 7, 2010
Appl. No.:
13/513523
Inventors:
Holbrook Kohrt - Santa Clara CA, US
Roch Houot - Rennes, FR
Ronald Levy - Stanford CA, US
Arash Ash Alizadeh - San Mateo CA, US
Matthew J. Goldstein - Hillsborough CA, US
James Torchia - Stanford CA, US
International Classification:
A61K 39/395
A61P 35/00
US Classification:
4241741
Abstract:
Methods of enhancing the efficacy of antibody-directed cellular cytotoxicity (ADCC) for therapy directed to killing of tumor cells are disclosed. Cancer specific cell surface antigens are bound by monoclonal antibodies, thereby stimulating a cytotoxic T cell response characterized by an upregulation of cell surface expression of costimulatory molecules on the T cell. The ADCC response is augmented by the subsequent administration of a second antibody that is an agonist of the costimulatory molecule.

Methods Of Prognosis For Non-Hodgkin Lymphoma

US Patent:
2012013, May 31, 2012
Filed:
Oct 5, 2011
Appl. No.:
13/253491
Inventors:
Arash Ash Alizadeh - San Mateo CA, US
Ronald Levy - Stanford CA, US
Andrew J. Gentles - Menlo Park CA, US
Izidore S. Lossos - Miami FL, US
International Classification:
A61K 39/395
A61P 35/00
A61K 31/4375
A61K 31/56
A61K 31/66
A61K 31/704
US Classification:
4241331, 514110, 514 34, 514283, 514179
Abstract:
Measurement of a single gene expressed by tumor cells (LMO2) and a single gene expressed by the immune microenvironment (TNFRSF9), which determination may be referred to herein as a two gene score (TGS), powerfully predicts overall survival in patients with NHL, particularly overall survival in the context of anthracycline-based chemotherapy or co-treatment with anthracycline-based chemotherapy and anti-CD20 immunotherapy. It is shown herein that increased levels of LMO2 and TNFRSF9 correlate with a positive patient response and improved prognosis.

Methods And Systems For Analyzing Nucleic Acid Molecules

US Patent:
2022038, Dec 8, 2022
Filed:
Aug 16, 2022
Appl. No.:
17/820200
Inventors:
- Stanford CA, US
Maximilian Diehn - San Carlos CA, US
Arash Ash Alizadeh - San Mateo CA, US
Assignee:
The Board of Trustees of the Leland Stanford Junior University - Stanford CA
International Classification:
C12Q 1/6886
G16B 30/10
G16B 20/20
G16B 35/20
G16B 30/00
C12Q 1/6874
G16H 70/60
G16H 10/40
G16H 50/30
G16H 50/70
G16H 20/10
G16B 40/00
G16B 20/10
C12N 15/10
G16H 50/20
C12Q 1/6869
Abstract:
Processes and materials to detect cancer from a biopsy are described. In some cases, cell-free nucleic acids can be sequenced, and the sequencing result can be utilized to detect sequences derived from a neoplasm. Detection of somatic variants occurring in phase can indicate the presence of cancer in a diagnostic scan and a clinical intervention can be performed.

Methods To Assess Clinical Outcome Based Upon Updated Probabilities And Treatments Thereof

US Patent:
2022039, Dec 8, 2022
Filed:
Dec 30, 2021
Appl. No.:
17/646621
Inventors:
- Stanford CA, US
Arash Ash Alizadeh - San Mateo CA, US
Maximilian Diehn - San Carlos CA, US
Mohammad Shahrokh Esfahani - Mountain View CA, US
Assignee:
The Board of Trustes of the Leland Stanford Junior University - Stanford CA
International Classification:
G16H 20/40
A61B 5/00
G16H 50/20
Abstract:
Methods of treatment based on a prognosis as determined utilizing a Bayesian framework are provided. Clinical data is utilized within a Bayesian framework to obtain a prognosis of a medical disorder. A prognosis can be updated utilizing a Bayesian framework when subsequent clinical data is acquired, such as clinical data acquired during a treatment or clinical monitoring.

Methods And Systems For Analyzing Nucleic Acid Molecules

US Patent:
2022037, Nov 24, 2022
Filed:
Apr 27, 2022
Appl. No.:
17/661034
Inventors:
- Stanford CA, US
David M. Kurtz - San Carlos CA, US
Maximilian Diehn - San Carlos CA, US
Arash Ash Alizadeh - San Mateo CA, US
Assignee:
The Board of Trustees of the Leland Stanford Junior University - Stanford CA
International Classification:
G16B 20/20
C12Q 1/6886
Abstract:
Processes and materials to detect cancer, transplant rejection, or fetal genetic abnormalities from a biopsy are described. In some cases, nucleic acid molecules, such as cell-free nucleic acids, can be sequenced, and the sequencing result can be utilized to detect sequences indicative of a neoplasm, transplant rejection, or fetal genetic abnormality. Detection of somatic variants occurring in phase and/or insertions and deletions (indels) can indicate the presence of cancer, transplant rejection, or fetal genetic abnormalities in a diagnostic scan, and a clinical intervention can be performed.

Methods And Systems For Analyzing Nucleic Acid Molecules

US Patent:
2022034, Oct 27, 2022
Filed:
May 2, 2022
Appl. No.:
17/661730
Inventors:
- Stanford CA, US
Maximilian Diehn - San Carlos CA, US
Arash Ash Alizadeh - San Mateo CA, US
Assignee:
The Board of Trustees of the Leland Stanford Junior University - Stanford CA
International Classification:
C12Q 1/6886
G16B 30/10
G16B 20/20
G16B 35/20
G16B 30/00
C12Q 1/6874
G16H 70/60
G16H 10/40
G16H 50/30
G16H 50/70
G16H 20/10
G16B 40/00
G16B 20/10
C12N 15/10
G16H 50/20
C12Q 1/6869
Abstract:
Processes and materials to detect cancer from a biopsy are described. In some cases, cell-free nucleic acids can be sequenced, and the sequencing result can be utilized to detect sequences derived from a neoplasm. Detection of somatic variants occurring in phase can indicate the presence of cancer in a diagnostic scan and a clinical intervention can be performed.

Methods And Systems For Analyzing Nucleic Acid Molecules

US Patent:
2022025, Aug 11, 2022
Filed:
Dec 29, 2021
Appl. No.:
17/646472
Inventors:
- Stanford CA, US
Maximilian Diehn - San Carlos CA, US
Arash Ash Alizadeh - San Mateo CA, US
Assignee:
The Board of Trustees of the Leland Stanford Junior University - Stanford CA
International Classification:
C12Q 1/6886
C12Q 1/6869
Abstract:
Processes and materials to detect cancer from a biopsy are described. In some cases, cell-free nucleic acids can be sequenced, and the sequencing result can be utilized to detect sequences derived from a neoplasm. Detection of somatic variants occurring in phase can indicate the presence of cancer in a diagnostic scan and a clinical intervention can be performed.

Possible Relatives

Fard Alizadeh  Arash A Rahbar  Arash Soltani  Arash D Tehranzadeh 

NOTICE: You may not use BackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. BackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.